Literature DB >> 12528761

Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin.

K Malmqvist1, K P Ohman, L Lind, F Nyström, T Kahan.   

Abstract

OBJECTIVES: Several neurohormonal systems have been suggested to stimulate myocardial cell growth, and thus take part in the development of left ventricular (LV) hypertrophy. We studied associations between LV mass and markers of the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system, glucose homeostasis and leptin.
DESIGN: A total of 115 hypertensive patients with LV hypertrophy and two age- and gender-matched control groups consisting of 38 hypertensive patients without LV hypertrophy and 38 normotensive subjects were included. We examined determinants of the RAAS, plasma levels and 24-h urinary excretions of noradrenaline and adrenaline, plasma proinsulin, insulin, glucose, leptin and LV mass by echocardiography.
RESULTS: Plasma renin activity (PRA) and serum aldosterone were higher (both P < 0.001) in the LV hypertrophy group than in patients without LV hypertrophy and normotensive subjects (1.0 +/- 0.8, 0.2 +/- 0.2 and 0.2 +/- 0.2 ng mL(-1) h(-1), and 327 +/- 126, 269 +/- 146 and 221 +/- 80 pmol L(-1), respectively). PRA and aldosterone both related (P < 0.001) to LV mass index (r = 0.44 and 0.27, respectively). Catecholamine levels and excretions were similar in all three groups and did not relate to LV mass index. Proinsulin, insulin and leptin levels were all elevated in the hypertensive patients (P < 0.01), but proinsulin, insulin, insulin sensitivity (by the homeostasis model assessment) and leptin did not relate to LV geometry, when indexed for body size.
CONCLUSIONS: Plasma renin activity and serum aldosterone levels are elevated in hypertensive LV hypertrophy and relate to LV mass index. In addition to blood pressure, activation of the RAAS may be an important nonhaemodynamic mechanism in the control of LV hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12528761     DOI: 10.1046/j.1365-2796.2002.01053.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  18 in total

1.  Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease.

Authors:  Giuseppe Mulè; Emilio Nardi; Laura Guarino; Valentina Cacciatore; Giulio Geraci; Ilenia Calcaterra; Bruno Oddo; Francesco Vaccaro; Santina Cottone
Journal:  Hypertens Res       Date:  2015-01-08       Impact factor: 3.872

2.  Ethnicity and Left Ventricular Hypertrophy: Tools and Uncertainties.

Authors:  Daniel Piskorz
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-07-27

3.  Stress Reduction in the Prevention of Left Ventricular Hypertrophy: A Randomized Controlled Trial of Transcendental Meditation and Health Education in Hypertensive African Americans.

Authors:  Robert H Schneider; Hector F Myers; Komal Marwaha; Maxwell A Rainforth; John W Salerno; Sanford I Nidich; Carolyn Gaylord-King; Charles N Alexander; Keith C Norris
Journal:  Ethn Dis       Date:  2019-10-17       Impact factor: 1.847

4.  Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension.

Authors:  Mieczysław Litwin; Anna Niemirska; Joanna Sladowska; Jolanta Antoniewicz; Joanna Daszkowska; Aldona Wierzbicka; Zbigniew T Wawer; Ryszard Grenda
Journal:  Pediatr Nephrol       Date:  2006-03-25       Impact factor: 3.714

Review 5.  Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.

Authors:  Carlos M Ferrario; Adam E Mullick
Journal:  Pharmacol Res       Date:  2017-05-29       Impact factor: 7.658

6.  The association between left ventricular hypertrophy and biomarkers in patients on continuous ambulatory peritoneal dialysis.

Authors:  Sang-Ho Park; Se-Whan Lee; Seung-Jin Lee; Won-Yong Shin; Dong-Kyu Jin; Hyo-Wook Gil; Jong-Oh Yang; Eun-Young Lee; Sae-Yong Hong
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

Review 7.  Aliskiren--mode of action and preclinical data.

Authors:  Dominik N Müller; Wolfgang Derer; Ralf Dechend
Journal:  J Mol Med (Berl)       Date:  2008-04-29       Impact factor: 4.599

Review 8.  Aliskiren: a review of its use in the management of hypertension.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Brain natriuretic peptide as a potential novel marker of salt-sensitivity in chronic kidney disease patients without cardiac dysfunction.

Authors:  Mutsuharu Hayashi; Yoshinari Yasuda; Susumu Suzuki; Manaka Tagaya; Takehiro Ito; Tomohito Kamada; Masataka Yoshinaga; Yoshinori Sugishita; Wakaya Fujiwara; Hiroatsu Yokoi; Yukio Ozaki; Hideo Izawa
Journal:  Heart Vessels       Date:  2016-07-06       Impact factor: 2.037

Review 10.  The metabolic syndrome and its relationship to hypertensive target organ damage.

Authors:  Giuseppe Mulè; Giovanni Cerasola
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-03       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.